DrugDashboards

Febuxostat

Febuxostat · FEBUXOSTAT 80 mg/1 · Tablet, Film Coated · Oral · NorthStar RxLLC

NDC 16714-0060-01 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price has fallen 37% in a year, to $0.2810 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.2810per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$1.86per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$0.2810per TABweighted avg manufacturer price $0.1085 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 72205-0029-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.8228per unit
middle half $0.5062$2.57 · 4,448 plans · Apr 1, 2026
Est. net of rebates
≈ $0.8228
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
81%of plans cover it
tier 3 · prior auth 7% · step therapy 64% · qty limit 29%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.

NADAC price per unit

$0$0.5$1.00$1.50Sep 2021Sep 2026$0.281
61 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$8.43
#90 count
$25.29

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$8,108
307 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 33% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for febuxostat (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA205467
TE code
AB
Approval date
Jul 1, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingMar 4, 2024
    SUN PHARMACEUTICAL INDUSTRIES INCCGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
  • Class II · OngoingMar 4, 2024
    SUN PHARMACEUTICAL INDUSTRIES INCCGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Manufacturers of Febuxostat (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
American Health PackagingFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Aphena Pharma Solutions - Tennessee, LLCFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCFEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsFEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsFEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
NorthStar RxLLCFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
NorthStar RxLLCFEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCFEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCFEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals, Inc.FEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals,Inc.FEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.FEBUXOSTAT 80 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.FEBUXOSTAT 40 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsFEBUXOSTAT 40 mg/1Jul 15, 2026Jul 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Febuxostat — NDC 16714-0060-01," retrieved September 3, 2026, https://drugdashboards.com/drug/16714006001.

Free to cite with attribution — see how the data is put together.